Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood sugar swings after a heart attack may reveal hidden dangers

NCT ID NCT06014112

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether blood sugar patterns, measured continuously with a wearable sensor, can predict serious heart problems in the year following a heart attack. Researchers will enroll 850 people hospitalized with acute coronary syndrome and track their glucose levels for up to two weeks. The goal is to see if glucose variability—not just a single blood sugar reading—offers a better warning of future heart attacks, strokes, or heart failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Freestyle Libre Pro iQ continuous glucose monitor
What this could lead to
If blood sugar patterns measured by this device predict future heart problems, doctors could use it to identify high-risk patients and tailor follow-up care.
What could go wrong
This is an observational study, not a treatment trial. It may find no strong link between glucose patterns and heart events, or the device may not be practical for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 850 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with ACS managed in a cardiac intensive care unit (ICU). The diagnosis of ACS will be made in the presence of chest pain with ST-segment elevation on the ECG for STEMI or ST-segment change and/or a positive troponin cycle (values in accordance with the center's protocol) for NSTEMI. Exclusion Criteria: * Subjects in cardiogenic or septic shock * Subjects with ACS initially managed in a non-investigating center * Failure to obtain free, informed, written consent signed by the participant and investigator upon admission to the ICU * Person participating in another research study with an ongoing exclusion period * Subjects participating in a study that may have an impact on post ACS prognosis * Person deprived of his or her rights, person under guardianship or curatorship * Person deprived of liberty (by judicial or administrative decision) * Persons whose physical and/or psychological health is severely impaired, which, in the opinion of the investigator, may affect the participant's compliance to the study * Pregnant or breastfeeding women * Person who is not affiliated to a social security system or who is a beneficiary of such a system.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Cardiovascular event Continuous glucose measurement Glycemic variability

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Lariboisière Hospital

    RECRUITING

    Paris, 75010, France

  • APHP - Hôpital Européen Georges Pompidou

    RECRUITING

    Paris, 75015, France

  • Hospital of Béziers

    RECRUITING

    Béziers, 34500, France

  • Hospital of Pau

    RECRUITING

    Pau, 64046, France

  • University Hospital of Bordeaux

    RECRUITING

    Bordeaux, 33604, France

  • University Hospital of Montpellier

    RECRUITING

    Montpellier, 34295, France

  • University Hospital of Nîmes

    RECRUITING

    Nîmes, 30029, France

  • University Hospital of Toulouse

    RECRUITING

    Toulouse, 31059, France

  • Vannes Bretagne Atlantique Hospital

    RECRUITING

    Vannes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.